Krystal Biotech, Inc. KRYS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s stock-based comp?
- Krystal Biotech, Inc. (KRYS) reported stock-based comp of $13.61M in Q1 2026.
- How has Krystal Biotech, Inc.'s stock-based comp changed year-over-year?
- Krystal Biotech, Inc.'s stock-based comp increased by 1.0% year-over-year, from $13.48M to $13.61M.
- What is the long-term trend for Krystal Biotech, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s stock-based comp has grown at a 37.3% compound annual growth rate (CAGR), from $15.32M to $54.51M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock or options.
- How do you interpret stock-based comp?
- High levels may indicate aggressive talent retention strategies but also signal potential shareholder dilution.
- How does stock-based comp compare across companies?
- Highly prevalent in high-growth biotech and technology sectors for talent acquisition.